Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
$0.34
-1.7%
$0.42
$0.31
$2.70
$5.44M1.31219,783 shs231,661 shs
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
$1.27
-0.8%
$1.24
$1.01
$65.00
$5.56M2.24327,134 shs44,411 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.16
-4.2%
$3.08
$1.75
$9.37
$5.11M1.38828,254 shs62,112 shs
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
$0.00
$0.00
$0.00
$0.42
$1.16M2.25511,766 shs44,014 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
+4.67%+1.50%-17.15%-57.25%-86.15%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
+0.79%-0.78%+13.27%-8.57%-82.80%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-0.30%-2.94%+4.10%+7.14%+1,525.62%
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
0.00%+61.54%0.00%+200.00%-81.74%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
3.2311 of 5 stars
3.52.00.00.04.41.71.3
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.6931 of 5 stars
0.03.00.00.03.30.00.6
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.4276 of 5 stars
0.03.00.00.03.30.00.0
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
3.00
Buy$8.502,406.64% Upside
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/AN/AN/AN/A$1.44 per shareN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/A$0.67 per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$13.97M0.37N/AN/A$3.01 per share1.05
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
$62.84M0.02N/AN/A($0.05) per share-0.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$15.42M-$1.49N/AN/AN/AN/A-177.27%-141.06%8/11/2025 (Estimated)
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-$51.60M-$78.00N/AN/AN/AN/AN/A-172.89%8/12/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$4.84M-$4.02N/AN/AN/A-26.82%-68.98%-26.39%6/16/2025 (Estimated)
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
-$572.84MN/A0.00N/AN/AN/AN/AN/A

Latest SRNEQ, INDP, MBIO, and SNOA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$0.41-$0.32+$0.09-$0.32N/AN/A
5/14/2025Q1 2025
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A-$0.05N/A-$0.05N/AN/A
3/13/2025Q4 2024
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$0.41-$0.38+$0.03-$0.38N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/A
3.42
3.42
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A
0.40
0.40
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.34
2.49
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
7.06%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
9.95%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
0.02%

Insider Ownership

CompanyInsider Ownership
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
20.60%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.21%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.90%
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
616.03 million9.96 millionNot Optionable
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1004.38 million952,000Not Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.62 million1.55 millionNot Optionable
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
800551.28 million536.95 millionNot Optionable

Recent News About These Companies

Sorrento Announces New Board Member

New MarketBeat Followers Over Time

Media Sentiment Over Time

Indaptus Therapeutics stock logo

Indaptus Therapeutics NASDAQ:INDP

$0.34 -0.01 (-1.68%)
As of 04:00 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Mustang Bio stock logo

Mustang Bio NASDAQ:MBIO

$1.27 -0.01 (-0.78%)
As of 04:00 PM Eastern

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.16 -0.14 (-4.24%)
As of 03:59 PM Eastern

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Sorrento Therapeutics stock logo

Sorrento Therapeutics OTCMKTS:SRNEQ

$0.0021 0.00 (0.00%)
As of 06/11/2025

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.